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The Role of Melanin Concentrating Hormone (MCH) in
the Central Chemoreflex: A Knockdown Study by siRNA
in the Lateral Hypothalamus in Rats
Ningjing Li, Eugene Nattie, Aihua Li*
Department of Physiology and Neurobiology, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, United States of America
Abstract
Melanin concentrating hormone (MCH), a neuropeptide produced mainly in neurons localized to the lateral hypothalamic
area (LHA), has been implicated in the regulation of food intake, energy balance, sleep state, and the cardiovascular system.
Hypothalamic MCH neurons also have multisynaptic connections with diaphragmatic motoneurons and project to many
central chemoreceptor sites. However, there are few studies of MCH involvement in central respiratory control. To test the
hypothesis that MCH plays a role in the central chemoreflex, we induced a down regulation of MCH in the central nervous
system by knocking down the MCH precursor (pMCH) mRNA in the LHA using a pool of small interfering RNA (siRNA), and
measured the resultant changes in breathing, metabolic rate, body weight, and blood glucose levels in conscious rats. The
injections of pMCH-siRNA into the LHA successfully produced a ,62% reduction of pMCH mRNA expression in the LHA and
a ,43% decrease of MCH levels in the cerebrospinal fluid relative to scrambled-siRNA treatment (P = 0.006 and P = 0.02
respectively). Compared to the pretreatment baseline and the scrambled-siRNA treated control rats, knockdown of MCH
resulted in: 1) an enhanced hypercapnic chemoreflex (,42 & 47% respectively; P , 0.05) only in wakefulness; 2) a decrease
in body weight and basal glucose levels; and 3) an unchanged metabolic rate. Our results indicate that MCH participates not
only in the regulation of glucose and sleep-wake homeostasis but also the vigilance-state dependent regulation of the
central hypercapnic chemoreflex and respiratory control.
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Introduction
Melanin concentrating hormone (MCH), a 17-amino acid
neuropeptide, was originally isolated from the pituitary gland of
salmon where it controls skin pigmentation [1]. In mammals,
MCH is mainly synthesized in neurons of the lateral hypothalamus
and zona incerta in the central nervous system (CNS), where it is
posttranslationally cleaved from a larger precursor molecule,
prepro-MCH (pMCH). The axons of hypothalamic MCH-
containing neurons project diffusely to multiple sites in the CNS
and the MCH receptors are widely distributed throughout the
brain [2,3], suggesting multiple functions for MCH.
Neuropharmacological studies in rats and an MCH-overex-
pressing mouse model have demonstrated important roles of
MCH in the regulation of body weight and food intake [4,5].
MCH also participate in the balance of the sleep-wake cycle [6,7].
Recent studies showed that central administration of MCH into
lateral ventricle (i.c.v.) or nucleus tractus solitarius (NTS) caused
depressor and bradycardiac responses in both anesthetized and
conscious rats [8,9]. Intrathecal injection of MCH produced a
dose-dependent hypotension, bradycardia, and sympathetic de-
pression, and attenuated the sympathetic response to stimulation
of peripheral (anoxia, ,4.4% O2) or central (hyperoxic hyper-
capnia 10% CO2/93% O2) chemoreceptors [10]. This evidence
suggested a role of MCH in autonomic functions.
Anatomical studies have suggested a role for MCH in
respiratory control. Injection of a transneuronal tracer into the
diaphragm showed that phrenic motoneurons are innervated by
both hypothalamic MCH and orexin neurons [11]. MCH neurons
send projections to many brain sites that contain putative central
chemoreceptors, such as the locus coeruleus (LC), the dorsal
raphe, the NTS, and the area of retrotrapezoid nucleus (RTN)
[3,12–15]. In addition, in the lateral hypothalamic area (LHA),
MCH neurons are closely intermingled with chemosensitive orexin
neurons, and these two types of neurons are interconnected
[11,16–19]. Orexin induces depolarization of MCH neurons by
evoking a direct inward current and by increasing excitatory
synaptic activity [20,21]. MCH reduces glutamate release at
presynaptic terminals and blocks orexin-A mediated enhancement
of action potential generation in orexin neurons [22]. Orexin is
known to participate in the regulation of cardiorespiratory
function and in the central hypercapnic chemoreflex [23,24]
while the role of MCH in these functions is poorly understood.
Here we hypothesize that MCH also participates in regulation of
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the central chemoreflex and that suppression of MCH activity will
significantly increase the central hypercapnic chemoreflex.
RNA interference (RNAi) is a mechanism for highly selective
and reversible gene suppression [25], and the small interfering
RNA (siRNA) can bind to the specific messenger RNA (mRNA)
molecules and decrease their activity via preventing an mRNA
from producing a protein [25]. In rat using siRNA, Chen at al.
successfully knocked down the prepro-orexin in the LHA, the
same area where the MCH neurons reside [26]. In this study, we
utilized a pool of siRNA to knock down the expression of the
precursor gene, pMCH, which encodes the production of MCH in
the LHA, to assess the role of MCH in the central chemoreflex.
We measured the hypercapnic ventilatory response, together with
body weight, body temperature, metabolic rate, glucose levels in
wakefulness and sleep before and after knockdown and in controls
injected with scrambled siRNA.
Methods
Ethical Approval
All animals were treated humanely and all experiments were
conducted in strict accordance with the guidelines of the National
Institutes of Health for animal use and care using a protocol
approved by the Institutional Animal Care and Use Committee
(IACUC) at the Geisel School of Medicine at Dartmouth College.
All surgical procedures were performed under ketamine/xylazine
anesthesia, and all efforts were made to minimize suffering.
Animals
A total of 37 adult Sprague–Dawley male rats (250–300 g;
Harlan Laboratories, IN) were used in this study. All the animals
were individually housed under 12 h: 12 h light: dark cycle (lights
on at 12:00 AM, off at 12:00 PM) at 2261uC. Food and water
were provided ad libitum. At the conclusion of the experiments,
the rats were killed by intraperitoneal (i.p.) injection of a
euthanasia solution, Euthasal (0.3 ml/kg, Virbac AH, Inc, TX,
USA).
Experimental design
Two sets of experiments were designed to evaluate the effects of
pMCH knockdown via pMCH-siRNA, and they are: 1) to verify,
in vitro, the effectiveness of the pMCH siRNA treatment and
examine the levels of MCH peptide in the CSF following the
pMCH siRNA administration, and 2) to evaluate, in vivo, the
effects of a lower level of MCH in the CNS on body weight,
glucose homeostasis, metabolic rate, and hypercapnic ventilatory
response in wakefulness and sleep.
Experiment 1
In the first set of experiments, we verified the target effects of the
pMCH siRNA by performing a real-time PCR for mRNA
expression of pMCH, orexin-A, and orexin receptor 1 (OX1R) in
the LHA, and a fluorescent enzyme immunoassay (EIA) for the
protein levels of MCH in the CSF.
Surgery and siRNA injections. The animals were randomly
divided into 3 groups with 5 animals in each group. After
intramuscular (i.m.) administration of ketamine (100 mg/kg,
Putney, Inc. Portland, ME, USA) and xylazine (15 mg/kg, Lloyd
Labs, Walnut, CA, USA) cocktail, rats in Group 1 were bilaterally
injected with a pool of pMCH siRNA (0.06 nmol in 0.3 ml water;
ID nos: s128229, s217872, s217873, Ambion, Applied Biosystem,
USA; Table 1). Animals in Group 2 received injections of
scrambled sequences (scrambled siRNA), which have no homology
to known rat genes, as control (0.06 nmol in 0.3 ml water; Ambion
In Vivo Negative Control #1 siRNA, Applied Biosystem, USA;
Table 1). Rats in Group 3 received injections with artificial CSF
(aCSF, 0.3 ml). All injections were made into the LHA using a
Hamilton syringe with two injections on each side. Coordinates
[27] for the LHA target site were: 3–3.4 mm caudal from bregma
and 1–2 mm lateral to the midline, with a depth of 8–8.8 mm
from the surface of the skull. Forty-eight hours after treatment, the
animals were sacrificed with an overdose of Euthasal (0.3 ml/kg,
i.p.). 48 hours post injection, the hypothalamus was quickly
dissected out, weighed, and immediately immersed in RNAlater
RNA stabilization reagent (5 ml, Qiagen, Valencia, CA, USA) and
subsequently stored at 4uC until processed for RNA extraction.
RNA extraction and Real-time PCR. Total RNA was
isolated from the dissected hypothalamic tissue using QIAzol lysis
reagent according to the manufacturer’s manual (Invitrogen,
Carlsbad, CA, USA) and purified on RNeasy Lipid Tissue Mini
Kit columns (Qiagen, Valencia, CA, USA) with on-column DNase
digestion using the RNase-Free DNase set (Qiagen, Valencia, CA,
USA). Six hundred ng of total RNA was reverse-transcribed using
the iScriptc DNA synthesis kit (Bio-Rad, Hercules, CA, USA)
according to the manufacturer’s directions. Relative mRNA
expression levels of genes of interest were measured using the 59-
fluorogenic nuclease assay in real-time quantitative PCR using
TaqMan chemistry on the ABI 7300 Prism real-time PCR
instrument (Applied Biosystems, Carlsbad, CA, USA). The
pMCH, orexin-A, OX1R, and cyclophilin A (cyc A) primer/
MGB probe sets were obtained from Applied Biosystems assays-
on-demand (vendor ID nos: Rn00561766, Rn00565995,
Rn00565032 and Rn00690933, respectively). PCR was conducted
using the following cycle parameters: 50uC for 2 min, 95u for
12 min for the first cycle, followed by 40 cycles of 95u for
20 seconds and 60u for 1 min. Analysis was performed using the
sequence detection software supplied with the ABI 7300. The
relative quantification was performed using the comparative
threshold cycle (Ct) with the DCt values determined by subtracting
the values of the reference control gene from the target gene Ct
values. The difference in the mRNA expression levels between the
groups was expressed as 22DDCt, where DDCt equals the
difference in DCt between the treatment and scrambled siRNA
rats. The levels of the gene expression were calculated and
presented as percentage (%) of the fold change.
CSF collection and EIA. CSF was collected from the cistern
magna via puncture of the atlanto-occipital membrane with a
28K G insulin syringe (1 mL, BD SafetyGlide, USA) under
anesthesia (ketamine/xylazine cocktail, 100/15 mg/kg, i.p.)
72 hrs post-injection in all three groups and was immediately
frozen and stored in 280uC. For better detection, CSF was 1:1
diluted in the 1x assay buffer provided in the commercial
Fluorescent EIA Kit (FEK-070-47, Phoenix Pharmaceuticals,
CA, USA). The concentration of MCH was measured according
to the manufacturer’s manual of the kit. Standard curves of MCH
were prepared for each assay by mixing different concentrations of
non-biotinylated MCH with a fixed concentration of biotinylated-
MCH peptide. The absorbance was measured in a 96-well plate
reader (BioTek Synergy 2, Winooski, VT, USA). Absorbance
results (pg/ml) were log transformed.
Experiment 2
Surgery and siRNA Injections. Twenty two rats were
anesthetized using the method described above for Experiment 1
and surgically implanted with electroencephalogram (EEG) and
electromyogram (EMG) electrodes (PlasticsOne Inc., VA, USA)
and a telemetric temperature probe (Data Sciences International,
MN, U.S.A) placed in the abdominal cavity. The detailed surgical
Knockdown of pMCH mRNA Expression Enhances Central Chemoreflex
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procedures have been described in an earlier paper [28]. Briefly,
three EEG electrodes were screwed onto the skull and two EMG
electrodes were inserted under the dorsal neck muscles with all
electrode wires connected to a six-prong plastic pedestal (Plastics
One Inc., VA, USA), which was attached to the skull by
cranioplastic cement (Lang Dental Manufacture, Co., Inc.,
Wheeling, IL, USA). Two holes were drilled on each side of the
skull with coordinates: 3–3.4 mm caudal from bregma and 1–
2 mm lateral to the midline to allow access to the LHA later [27].
A sterile telemetry temperature probe (TA-F20, Data Sciences, St
Paul, MN, USA) was implanted into the peritoneal cavity. After
the incisions were sutured, the animals were allowed to recover for
at least 7 days.
After the pretreatment baseline experiments, a pool of siRNA
(pMCH siRNA or scrambled siRNA, 0.06 nmol in 0.3 ml water
mixed with red IX retrobeads (LumaFluor, Inc. Durham, NC,
USA) was injected into the LHA in rats under general anesthesia.
Coordinates for the LHA target site were: 3–3.4 mm caudal to
bregma; 1–2 mm lateral to the midline and 8–8.8 mm from the
surface of the skull [27].
Blood glucose and Body Weight. Body weight and blood
glucose level were measured before each physiological experiment.
To collect blood sample for glucose measurement, a small cut was
made near the end of the rat tail, and the drops of blood were
collected directly on the test strip placed in the blood glucometer
(Contour, Bayer HealthCare LLC, USA).
Ventilation, Oxygen Consumption and Temperature
Measurement. The methods used to measure ventilation
(_VE), body temperature (Tb) and oxygen consumption (_VO2) in
conscious rats were those commonly used in our lab [29]. Briefly,
we used the whole body plethysmograph with a volume of 7.6 L
and a 3.5 L top designed to protect the head pedestal. The
chamber was connected to a similarly sized reference chamber by
a high resistance port. Analog output from the pressure transducer
was sampled at 150 Hz and converted into digital signals by using
the DATAPAC 2K2 system (RUN Technologies, Mission Viejo,
CA, USA) on a computer. The rate of gas inflow was maintained
at $1.4 L min21 with the plethysmograph at atmospheric
pressure. CO2 and O2 fractions were sampled from the outflow
at ,100 ml min21 by a CO2 and O2 gas analyzer (AEI
Technologies, INC., Pittsburgh, PA, USA). The plethysmograph
was calibrated by obtaining pressure response data from five
0.3 ml air injections using a 1 ml syringe before each experiment
began. Breath-by-breath analysis was performed using the
pressure deflections and the respiratory cycle time for each breath.
Tidal volume (VT) and respiratory frequency (fR) were
calculated per breath to estimate ventilation per breath. VT was
calculated by using the equation published in 1970 [30]. By using
EEG and EMG criteria, _VE was calculated for each animal
during both quiet wakefulness and NREM sleep and was
expressed as mean values. _VO2 was calculated by application of
the Fick principle using the difference in O2 content between
inflow and outflow air and the flow rate as described previously
[29]. Core body temperature was measured continuously using the
signals from the telemetric temperature probe surgically placed in
the abdomen. The chamber temperature was measured using a
thermometer inside the plethysmograph.
Determination of vigilance state
Raw EEG and EMG signals from electrodes on the skull and in
the neck muscles were sampled at 150 Hz, filtered at 0.3–70 and
0.1–100 Hz, respectively, and were recorded by the DATAPAC
system across the experimental period. A fast Fourier transform
was performed on the EEG and EMG signals at 4.0 s long epochs
to determine the vigilance states as previously described [28,31].
The vigilance states were categorized as wakefulness, NREM, and
REM sleep. Since not all rats have data in REM sleep in both air
and 5% CO2 breathing conditions the data in REM sleep are
omitted here.
Experimental protocol
The physiological measurements were performed before (base-
line) and 72 hour after being injected with siRNA (scrambled
siRNA or pMCH siRNA) during the early dark period. For the
ventilatory hypercapnic chemoreflex (CO2 response), the rats were
allowed to acclimate for 1 h under room air (23–25uC) in the
plethysmograph chamber. In order to obtain data in both
wakefulness and NREM sleep we recorded baseline data in room
air for 45 min, and then 5% CO2 for another 45 min. After
pretreatment baseline experiments, the rats were injected with
siRNA (scrambled siRNA or pMCH siRNA) through the two pre-
drilled holes on the skull during the 1st surgery under general
anesthesia.
Anatomy analysis
Upon completion of the experiments, the rats were euthanized
with an overdose of Euthasal. The whole brain was dissected,
frozen, and sectioned at 30 mm thickness with a Reichert–Jung
cryostat (Leica Microsystems, Buffalo Grove, IL, USA). The
sections were then examined under fluorescence microscopy
(Olympus, NJ, USA) to verify the injection sites. The third
ventricle and the fornix were used as the landmarks to determine
injection sites in the LHA.
Statistical analysis
All data are presented as mean 6 standard error of the mean
(S.E.M.). We used SigmaPlot 11.0 (Systat Software Inc., San Jose,
CA, USA) to apply one-way ANOVA separately to assess the
effects of treatments on mRNA expression of pMCH, orexin-A,
and OX1R with application of Bonferroni’s test for post hoc
Table 1. Sequences of siRNA.
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comparisons. For EIA data, we applied unpaired t-test to MCH
levels in the CSF after pMCH siRNA or scrambled siRNA
injections. For analysis of _VE/_VO2 and D_VE, we applied two
way RM ANOVA with gas and treatment as the two factors then
applying Bonferroni’s post hoc test to compare pre- and post-
treatment; for comparisons between treatments, we used a two
way ANOVA with treatment and gas as factors then applying
Bonferroni’s test for post hoc comparisons. To further investigate
whether treatment effects were dependent on gas components or
vigilance state, we applied a three way ANOVA with treatment,
gas and vigilance state as factors. For the analysis of body weight,
glucose levels and sleep we applied paired t-test to assess the effects
before and after siRNA injections and one way ANOVA with
Bonferroni’s post hoc test to compare effects among groups.
Results
Anatomic Analysis
A representative example of the anatomic locations of siRNA
injection sites (bilateral) indicated by fluorescent beads (bright
white) in the LHA is shown in Fig. 1A. There is noticeable overlap
among injection sites. The schematic coronal cross-section of the
hypothalamus demonstrates the relationship of the injection sites
(black filled symbols) and the distribution of hypothalamic MCH
neurons (small grey dots) drawn according to the MCH-
immunoreactive perikarya staining in the LHA of adult rats
[16,27] (Fig. 1B). Injection sites found outside the LHA, e.g.,
Fig. 1C & D, were considered as off-target injections.
mRNA expression
Real-time PCR data showed an average 62% down-regulation
of pMCH mRNA 48 hours post injection of pMCH siRNA into
the LHA relative to that of both scrambled siRNA and aCSF
control groups (Fig. 2A; P = 0.006, one way ANOVA, N = 5 each
group). Bonferroni’s post hoc test showed pMCH mRNA was
significantly lower in the pMCH siRNA group compared to that in
the scrambled siRNA group (N = 5, P,0.05) or to that in the
aCSF group (N = 5, P,0.01). There was no significant difference
in pMCH mRNA expression between the scrambled siRNA group
and the aCSF group (N = 5, P.0.05). pMCH mRNA levels in the
pMCH siRNA group were: mean, 37.5% of the controls; range,
26.3%–48.7%; controls being the scrambled siRNA group: mean,
100%; range, 69.7%–131.7%; in the aCSF group: mean, 107.3%
of the controls; range, 66.85%–146.15%. We also tested whether
knocking down pMCH has non-specific effects on the adjacent
neuronal groups, e.g., orexin neurons, since MCH and orexin
neurons are intermingled within the LHA (Van den Pol, et al
2004; Rao et al, 2008). There was a trend towards an increase
(,54%) in orexin-A mRNA levels in the pMCH siRNA treated
group; it was not statistically significant. No significant changes
were observed in OX1R mRNA levels in any group. These data
demonstrated that pMCH siRNA has specific targeted effects of
on pMCH mRNA.
MCH level in CSF
Fluorescent EIA showed that knocking down pMCH with
pMCH siRNA also resulted in a ,43% decrease of MCH levels in
CSF compared to that of scrambled siRNA treated rats (mean 6
s.e.m.; Fig. 2B, N = 5, 6, respectively; P = 0.02, unpaired t-test).
MCH peptide levels (1:1 diluted in 1x assay buffer) were
104.967.8 pg/ml and 60.069.7 pg/ml in the CSF in scrambled
siRNA group and pMCH siRNA group, respectively, and the
lowest level was observed at 48 hr post treatment.
Hypercapnic chemoreflex
Compared to the pre-injection baseline, pMCH siRNA induced
a 42% increase in _VE/_VO2 while breathing 5% CO2 during
quiet wakefulness (Fig. 3, left): before injection, _VE/_VO2
breathing 5% CO2 was 142610 ml min
21 (100 g)21 and after
injection was 202615 ml min21 (100 g)21 (N = 6, P = 0.002, two
way RM ANOVA, Bonferroni’s post hoc test). In the scrambled
siRNA group, no significant difference was observed before and
after scrambled-siRNA injection (Fig. 3A middle). There was no
significant difference of _VE/_VO2 in RA before and after siRNA
injection in either group. Compared to the rats injected with
scrambled siRNA, pMCH siRNA injection also induced a 47%
higher _VE/_VO2 in 5% CO2 (Fig. 3, right; N = 6, P,0.001, two
way ANOVA, Bonferroni’s post hoc test): _VE/_VO2 was
202615 ml min21 (100 g)21 and 13767 ml min21 (100 g)21 in
pMCH siRNA and scrambled siRNA groups, respectively. There
were no significant changes in _VE/_VO2 induced by siRNA
injections during NREM sleep in either RA or 5% CO2 (Fig. 3B).
We also conducted a three way ANOVA with Bonferroni’s test to
assess the dependence of the effects of treatment on gas
components (RA or CO2) and vigilance states (wakefulness or
NREM sleep). There is a significant interaction between treatment
and gas components. In RA, no significant difference was found
in _VE/_VO2 comparing pMCH siRNA to scrambled siRNA
treatment (P = 1); in 5% CO2, pMCH siRNA treated rats had a
higher _VE/_VO2 than that in the scrambled siRNA group
(P,0.001). The effects of pMCH siRNA were vigilance-state
dependent; the effects on _VE/_VO2 were present only in
wakefulness (P = 0.002); not in NREM sleep (P = 0.602).
Since _VO2 was not affected by pMCH-siRNA the enhanced
_VE/_VO2 response to hypercapnia induced by knockdown of
pMCH was primarily due to increased ventilation. Fig. 4A shows
that the CO2 response, shown as D_VE, was enhanced after
knocking down pMCH mRNA expression, from 11768 ml min21
(100 g)21 pre-injection to 233618 ml min21 (100 g)21 post-
injection in quiet wakefulness (N = 6, P,0.001, two way RM
ANOVA, Bonferroni’s post hoc test) but not in NREM sleep
(Fig. 4B, N = 6, P = 1, two way RM ANOVA, Bonferroni’s post
hoc test). No such effect was found in the scrambled siRNA
injected group. The CO2 response in the pMCH group is
significantly higher than that in the scrambled siRNA treated
group (N = 6, P,0.001, two way ANOVA, Bonferroni’s post hoc
test). The treatment effects on D_VE depended on what level of the
vigilance state was present. There was a statistically significant
interaction between treatment and vigilance state (P = 0.014). The
significant effects were in wakefulness.
Energy Balance
Fig. 5A shows that 72 hrs after bilateral injections of pMCH
siRNA, the rats had experienced an ,8% body weight loss; weight
pre-injection, 275.566.5 g; weight post-injection, 252.967.7 g
(N = 6, P = 0.046, paired t-test). In contrast, bilateral injection of
scrambled-siRNA did not cause any significant weight changes.
Fig. 5B shows that non-fasting basal glucose levels were reduced
by pMCH-siRNA injection compared to pre-injection baseline.
Glucose levels before pMCH siRNA injection were 11564 mg/dl
whereas after pMCH siRNA injection they dropped to 7962 mg/
dl, a 31% of decrease (N = 6, P = 0.031, paired t-test). This
response was not observed in the scrambled siRNA treated group.
There was no significant difference in the baseline glucose levels
between pMCH siRNA and scrambled siRNA treated groups
before injections (N = 6, P = 0.254, one way ANOVA, Bonferro-
ni’s post hoc test). However, after siRNA injection, pMCH siRNA
treated rats had lower glucose levels compared to that in those
Knockdown of pMCH mRNA Expression Enhances Central Chemoreflex
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receiving scrambled siRNA (N = 6, P = 0.012, one way ANOVA,
Bonferroni’s post hoc test).
Metabolic rate and body temperature were not affected by
either treatment (data not shown).
Discussion
In the present study, we demonstrated that specific knockdown
of MCH in the CNS via injection of pMCH-siRNA in LHA led to:
1) an increase in the ventilatory hypercapnic chemoreflex in
wakefulness but not NREM sleep; and 2) a decrease in body
weight and basal blood glucose levels in conscious, freely-moving,
and non-fasting adult rats.
Knockdown pMCH with siRNA
RNAi is a widely used potent method to suppress specific gene
expression in mammalian cells and study gene function. However
a critical issue in siRNA design is to guarantee that the designed
siRNA sequences are specific and free of off-target effect. The
actual mechanism of off-target effect is still unclear, however it
has been shown that a partial sequence homology between
siRNA and its unintended target is one of the contributing factors
[32,33]. How to evaluate and mitigate the off-target effect is a
very challenging issue particularly for the whole animal exper-
iments and human clinical trials [32]. In this study, to verify the
specificity and minimize the off-target effects we: 1) used a pool of
three pMCH siRNAs to silence the pMCH gene; 2) measured
both MCH mRNA expression and the protein level of MCH in
the CNS in both knockdowns and controls; 3) measured, in vivo,
the effects of MCH on respiratory response to hypercapnia and
glucose in both control and knockdown animals; 4) used
scrambled siRNA as one of the controls; 5) matched analysis of
the pMCH siRNA sequences with the gene database at GenBank;
6) measured orexin-A mRNA expression, which is produced by
Figure 1. Anatomic locations of the injection sites. (A) Representative cross section showing the injection sites (fluorescent beads) located
within the lateral hypothalamic area (LHA), two injections on each side (note: two injections were overlapping on one side). (B) Schematic
corresponding section of A illustrating the injection sites (black) and the distribution of MCH neurons (small grey dots, modified from (Paterson &
Hahn 2010)) in the LHA. (C) Representative section and (D) the schematic corresponding section from a rat showing the injection sites localized
outside the LHA in the hippocampus. Abbreviations: 3v, third ventricle; f, fornix; hip, hippocampus; mtt, mammillothalamic trac; VMH, ventromedial
hypothalamus. Scale bar represents 0.5 mm.
doi:10.1371/journal.pone.0103585.g001
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the adjacent orexin neurons in the LHA. Pooling multiple
siRNAs has been suggested as one way to reduce the off target
effects due to competition among the siRNAs in the pool [32,34].
Kittler et al., reported that pooling of multiple siRNAs to the
same target significantly reduced a number of cells and the
magnitude of off-target silencing relative to a single siRNA
in vitro [34]. Both in vitro MCH mRNA expression and MCH
protein measurements, and in vivo functional measurements of
the respiratory response to hypercapnia and changes of body
weight and basal glucose level demonstrated that we have
successfully knocked down pMCH in the LHA. Based on the
match analysis of the pMCH siRNA sequences with the database
at GenBank, the most likely off-target gene of the pMCH siRNAs
is Poly [ADP-ribose] polymerase 1 (PARP1) binding protein.
PARP1 is a product transcribed from the opposite strand of the
MCH gene; however, PARP1 binding protein mRNA is not
Figure 2. The effects of knockdown of pMCH mRNA expression on the expression levels of pMCH, orexin-A and orexin receptor 1
(OX1R) mRNA in the LHA (A) and MCH peptide levels in cerebrospinal fluid (CSF; B). (Mean 6 S.E.M.). The levels of pMCH, orexin-A, and
OX1R mRNA expression in the LHA were measured by RT-PCR 48 hrs post injections of aCSF (open bars), pMCH siRNA (filled bars) or scrambled siRNA
(hatched bars) into the LHA (A; N = 5 each group; one way ANOVA, Bonferroni’s post hoc test). MCH peptide levels in the CSF were measured by EIA
72 hrs post injections of pMCH siRNA (black bar) or scrambled siRNA (hatched bar) (N = 5 & 6 respectively; unpaired t-test). Significant difference is
indicated with *(P,0.05) or **(P,0.01).
doi:10.1371/journal.pone.0103585.g002
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present in the rat hypothalamus [35]. The other possible off-
target genes include TGFB-induced factor homeobox 2-like, X-
linked 2 (Tgif2lx2), osteopetrosis associated transmembrane
protein 1 (Ostm1), coiled-coil domain containing 124 (Ccdc124),
UFM1-specific peptidase 2 (Ufsp2), and pericentrin (Pcnt), genes
that are not physiologically relevant to MCH function. There-
Figure 3. The effects of knockdown of pMCH mRNA expression on the _VE/_VO2 response to hypercapnia. _V E/_V O2 ratio (Mean 6
S.E.M.) in room air (RA) and 5% CO2 before (filled circles) and 72 hrs after (open circles) injections of pMCH siRNA or scrambled siRNA during quiet
wakefulness (A) and NREM sleep (B) (N = 6; two way RM ANOVA, Bonferroni’s test). Significant difference is indicated with **(P,0.01) or ***(P,0.001).
doi:10.1371/journal.pone.0103585.g003
Knockdown of pMCH mRNA Expression Enhances Central Chemoreflex
PLOS ONE | www.plosone.org 7 August 2014 | Volume 9 | Issue 8 | e103585
fore, we conclude that the observed change of ventilatory
response to hypercapnia is due to knocking down of pMCH via
pMCH siRNAs in the LHA.
Our approach of using siRNA to knockdown the expression of
the pMCH mRNA was aimed at reducing the synthesis of MCH
and producing a reduction in MCH levels in the CNS for a short
Figure 4. The effects of knockdown of pMCH mRNA expression on CO2 chemoreflex. Effects of treatments on the changes of ventilation
from RA to CO2 (D_VE: the difference between ventilation in RA and in 5% CO2). D_VE before (Filled bars) and 72 hrs after (open bars) pMCH or
scrambled siRNA treatment during quiet wakefulness (A) and NREM sleep (B). (N = 6 each group, two way RM ANOVA, Bonferroni’s post hoc test)
(Mean 6 S.E.M.) Significant difference is indicated with *(P,0.05) or **(P,0.01).
doi:10.1371/journal.pone.0103585.g004
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period of time. Here we showed that the pMCH-siRNAs
efficiently lowered pMCH mRNA expression by ,62% in the
LHA (Fig. 2A) and decreased MCH levels by ,43% in the CSF
(Fig. 2B) while the levels of mRNA expression of orexin-A and
OX1R were not significantly affected by pMCH siRNA injections
in the LHA (Fig. 2A). However, aside from MCH, two other
peptides, neuropeptide-glutamic acid-isoleucine (NEI) and neuro-
peptide-glycine-glutamic acid (NGE), are also derived from the
same common precursor pMCH [36], and knocking down the
pMCH in the LHA may also reduce the levels of NEI and NGE in
Figure 5. The effect of knockdown of pMCH mRNA expression on body weight and glucose levels. Body weight before (filled bars) and
72 hrs after (open bars) pMCH siRNA injection or scrambled siRNA injection (N = 6 each group, paired t-test) (A). Basal glucose levels before (filled
bars) and 72 hrs after (open bars) pMCH siRNA or scrambled siRNA injection (N = 6 each group, paired t-test) (B). The pMCH siRNA treated group had
significant lower glucose levels than that of scrambled siRNA treated group (B; one way ANONA). (Mean 6 S.E.M.) Significant difference is indicated
with *(P,0.05).
doi:10.1371/journal.pone.0103585.g005
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the CNS [2,14,36]. At the present time, limited studies on NEI
and NGE have not demonstrated any biological and physiological
significance [2], however, a recent report suggest that NEI may
affect grooming behavior and motor activity [37].
MCH and hypercapnic chemoreflex
Our present study has demonstrated for the first time in conscious
animals that MCH is involved in central chemoreflex. Reduced
expression of the pMCH mRNA, which resulted in a lower MCH
level in the brain, led to an enhanced hypercapnic ventilatory
chemoreflex as demonstrated by increased _VE/_VO2 and D_VE in
rats in wakefulness (Fig. 3A & 4A). Since both metabolic rate and
body temperature were not affected by pMCH siRNA, we conclude
that the enhanced hypercapnic chemoreflex (_VE/_VO2 and D_VE)
observed in this study is primarily due to the ventilatory change
induced by knockdown of MCH expression. How MCH neurons
participate in regulation of the central hypercapnic chemoreflex is
not well understood at the present time. A study with injection of a
rabies virus transneuronal tracer in the diaphragm revealed that
MCH neurons have multisynaptic connections with the diaphragm
motoneurons [11]. MCH projections and MCHR1 are found in
many brain sites that contain central chemoreceptors, e.g., the
RTN, NTS, LC, dorsal and medullary raphe nucleus [3,12–15,38].
Presumably MCH neurons can directly alter the neuronal activity in
these putative chemoreceptor sites and thus change the chemosen-
sitivity of the central chemoreflex, or directly or indirectly modulate
the phrenic motor neuron activity.
In the LHA, MCH neurons are closely intermingled with
chemosensitive orexin neurons [11,16,17,19,20,39,40], and have a
reciprocal synaptic relationship with each other [41]. Orexins are
predominantly excitatory neuropeptides [42], whereas MCH is
primarily considered as an inhibitory neuropeptide [20,43–45]. In
brain slices, orexins directly and indirectly excite the MCH neurons
[20] while MCH attenuates orexin-A induced excitation in orexin
neurons [22]. Orexin and MCH neurons are physiologically
antagonistic in many aspects. In respect to the ventilatory hypercap-
nic chemoreflex, inhibition of the orexin system decreased the CO2
chemoreflex [24,31], while here we showed that decreased level of
MCH in the CNS increased the ventilatory CO2 chemoreflex. We
speculate that removing the inhibitory MCH influence on orexin
neurons in the LHA by knockdown of pMCH further facilitates
orexin excitatory effects on the central chemoreceptors and
subsequently induces an increased central hypercapnic chemoreflex.
That the enhanced hypercapnic chemoreflex was observed only in
wakefulness (not in NREM sleep) during the experimental hour in the
dark period in this study also indirectly support this hypothesis since
orexin is most active in wakefulness during the dark period [46].
Injection of MCH into the spinal cord significantly decreased
sympathetic responses to both anoxia and hypercapnia but the
respiratory (phrenic activity) response remained unchanged in
anesthetized rats (Egwuenu et al., 2012). In summary, our study
suggests that MCH, in contrast to orexin, acts to suppress the central
hypercapnic chemoreflex.
MCH and body weight, glucose level, metabolic rate and
body temperature
The rats treated with pMCH siRNA experienced an 11% body
weight loss at ,72 hrs after injection (Fig. 5A) in our study,
however all rats were in good health with no signs of dehydration
or stress. The weight loss resulted by decreased central MCH in
this study is consistent with the general role of MCH on feeding
and body weight as reported by other groups [4,5,47–51].
We also observed a significant reduction in the non-fasting basal
glucose levels after knocking down pMCH mRNA (Fig. 5B).
MCH is involved in the glucose regulation, which has been
discussed in detail in many recent publications [5,42,52–54].
Overexpression of MCH in mice leads to obesity and insulin
resistance [5,54], and in contrast, pMCH2/2 and MCH-neuron-
ablated mice are lean with improved insulin sensitivity [55,56].
The decreased non-fasting basal glucose levels after knockdown of
pMCH mRNA in our study may be the result of improved glucose
metabolism induced by lower levels of central MCH.
MCH and sleep homeostasis
MCH neurons discharge maximally during REM sleep and
occasionally during NREM and are silent during wakefulness [46].
However, the mechanism by which MCH affects the sleep-wake
cycle remains controversial at present time. We have decided not
to draw any conclusions on the effect of knocking down MCH on
the sleep-wake cycle for the following reasons. 1) Our current
study was optimized to evaluate the maximal changes of
ventilation in air-hypercapnic conditions in wakefulness and sleep
at the beginning of the dark period, and therefore these data only
reflected the changes of wakefulness-sleep during this particular
period. 2) Our siRNA induced change of MCH in the CNS was
short lasting. In our case, the lowest MCH mRNA expression was
observed at 48 hr post injection, and it came back to normal after
72 hr. We think that it is very difficult to study the effect of MCH
on sleep-wake cycle, which requires many hours of recording,
while the level of MCH in the CNS is not stable; 3) To accurately
address the issue of MCH knock-down effects on sleep will require
a different experimental design with more than 24 hr continuous
recording with steady level or levels of MCH in the CNS.
In conclusion, decreasing the level of MCH via knockdown of
pMCH mRNA expression in LHA and in the CNS: 1) enhanced
the ventilatory response to hypercapnia in wakefulness; and 2)
induced weight loss and lowered basal non-fasting glucose levels in
conscious rats. These data suggest that the neuropeptide MCH in
the LHA potentially functions as a negative feedback modulator in
regulation of the central chemoreflex and may be the link between
energy homeostasis and autonomic function.
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